BMO Capital Markets Boosts Valeant Pharmaceuticals International, Inc. (VRX) Price Target to $17.00

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) had its target price increased by equities researchers at BMO Capital Markets from $16.00 to $17.00 in a research report issued on Monday. The firm currently has a “market perform” rating on the specialty pharmaceutical company’s stock. BMO Capital Markets’ price objective would suggest a potential upside of 10.53% from the stock’s current price.

A number of other research firms have also recently issued reports on VRX. Vetr upgraded Valeant Pharmaceuticals International from a “buy” rating to a “strong-buy” rating and set a $14.26 price objective on the stock in a research report on Thursday, October 19th. ValuEngine cut Valeant Pharmaceuticals International from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Royal Bank Of Canada lowered their price objective on Valeant Pharmaceuticals International from $21.00 to $18.00 and set a “sector perform” rating on the stock in a research report on Friday, October 20th. Wells Fargo & Company dropped coverage on Valeant Pharmaceuticals International in a research report on Sunday, July 30th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $23.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Tuesday, August 29th. Five investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $17.22.

Shares of Valeant Pharmaceuticals International (VRX) traded up $0.03 during midday trading on Monday, reaching $15.38. The company’s stock had a trading volume of 19,960,200 shares, compared to its average volume of 17,998,627. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 4.84. The company has a market cap of $5,361.34, a P/E ratio of 2.50, a P/E/G ratio of 0.43 and a beta of -0.40. Valeant Pharmaceuticals International has a 52 week low of $8.31 and a 52 week high of $18.71.

TRADEMARK VIOLATION NOTICE: “BMO Capital Markets Boosts Valeant Pharmaceuticals International, Inc. (VRX) Price Target to $17.00” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://stocknewstimes.com/2017/11/13/bmo-capital-markets-boosts-valeant-pharmaceuticals-international-inc-vrx-price-target-to-17-00.html.

In other news, Director Schutter Richard U. De purchased 10,000 shares of the business’s stock in a transaction dated Monday, August 21st. The shares were acquired at an average price of $14.33 per share, with a total value of $143,300.00. Following the completion of the purchase, the director now directly owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 5.87% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of VRX. Ameriprise Financial Inc. increased its holdings in Valeant Pharmaceuticals International by 31.3% in the first quarter. Ameriprise Financial Inc. now owns 44,149 shares of the specialty pharmaceutical company’s stock valued at $487,000 after purchasing an additional 10,534 shares during the last quarter. Alliancebernstein L.P. increased its holdings in Valeant Pharmaceuticals International by 49.3% in the first quarter. Alliancebernstein L.P. now owns 39,664 shares of the specialty pharmaceutical company’s stock valued at $437,000 after purchasing an additional 13,092 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in Valeant Pharmaceuticals International by 33.7% in the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after purchasing an additional 2,763 shares during the last quarter. Vanguard Group Inc. increased its holdings in Valeant Pharmaceuticals International by 9.8% in the first quarter. Vanguard Group Inc. now owns 6,980,074 shares of the specialty pharmaceutical company’s stock valued at $76,990,000 after purchasing an additional 621,618 shares during the last quarter. Finally, Paloma Partners Management Co increased its holdings in Valeant Pharmaceuticals International by 12.0% in the first quarter. Paloma Partners Management Co now owns 27,996 shares of the specialty pharmaceutical company’s stock valued at $310,000 after purchasing an additional 2,996 shares during the last quarter. 46.61% of the stock is currently owned by institutional investors and hedge funds.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply